Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: A comparative study of molecular inhibitors and siRNA therapeutics

α3 integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer

(2021) Zhe Wang et al.   Acta Biomaterialia

Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer

(2021) Monika Kressin et al.   Cells

Emerging targeted drug delivery strategies toward ovarian cancer

(2021) Zhe Wang et al.   ADVANCED DRUG DELIVERY REVIEWS

Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma

(2020) Roberta Affatato et al.   Cancers

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance

(2020) Elodie Montaudon et al.   Nature Communications

Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and superb treatment of orthotopic glioblastoma

(2020) Qianyi Fan et al.   JOURNAL OF CONTROLLED RELEASE

Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation

(2020) Wenxing Gu et al.   JOURNAL OF CONTROLLED RELEASE

Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy

(2020) Yuan Li et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells

(2019) Linlin Chang et al.   Acta Pharmaceutica Sinica B

Epithelial ovarian cancer

(2019) Stephanie Lheureux et al.   LANCET

ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer

(2019) Xiaofei Xin et al.   ACS Applied Materials & Interfaces

Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability

(2019) Monika Raab et al.   NEOPLASIA

PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer

(2019) Moataz Reda et al.   CANCER LETTERS

Ovarian cancer statistics, 2018

(2018) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma

(2018) Yonghuan Mao et al.   Translational Oncology

Co-delivery of PLK1-specific shRNA and doxorubicin via core-crosslinked pH-sensitive and redox ultra-sensitive micelles for glioma therapy

(2018) Pu Wang et al.   Journal of Materials Chemistry B

Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes

(2018) Yanan Shi et al.   JOURNAL OF CONTROLLED RELEASE

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

(2017) Lainie P. Martin et al.   GYNECOLOGIC ONCOLOGY

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

(2017) Kathleen N. Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

Folate-mediated chemotherapy and diagnostics: An updated review and outlook

(2017) Leyuan Xu et al.   JOURNAL OF CONTROLLED RELEASE

Plk1 regulates contraction of postmitotic smooth muscle cells and is required for vascular homeostasis

(2017) Guillermo de Cárcer et al.   NATURE MEDICINE

PLK1, A Potential Target for Cancer Therapy

(2017) Zhixian Liu et al.   Translational Oncology

Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer

(2017) Akira Yokoi et al.   Nature Communications

PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

(2017) R. W. Naumann et al.   JOURNAL OF CLINICAL ONCOLOGY

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

(2016) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular interactions of polo-like kinase 1 in human cancers

(2016) Wayne Tiong Weng Ng et al.   JOURNAL OF CLINICAL PATHOLOGY

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor

(2016) J. Van den Bossche et al.   MEDICINAL RESEARCH REVIEWS

Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics

(2016) Rosie Elizabeth Ann Gutteridge et al.   MOLECULAR CANCER THERAPEUTICS

Physical Principles of Nanoparticle Cellular Endocytosis

(2015) Sulin Zhang et al.   ACS Nano

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   NATURE MEDICINE

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

(2014) H. Dohner et al.   BLOOD

Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review

(2014) Claudia Marchetti et al.   OncoTargets and Therapy

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

(2011) Ingrid E. Wertz et al.   NATURE

Surface Functionalization Using Catalyst-Free Azide−Alkyne Cycloaddition

(2010) Alexander Kuzmin et al.   BIOCONJUGATE CHEMISTRY

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

Knocking down barriers: advances in siRNA delivery

(2009) Kathryn A. Whitehead et al.   NATURE REVIEWS DRUG DISCOVERY

Size-Dependent Endocytosis of Nanoparticles

(2008) Sulin Zhang et al.   ADVANCED MATERIALS